These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21502982)

  • 1. RNAi-based therapeutic strategies for metabolic disease.
    Czech MP; Aouadi M; Tesz GJ
    Nat Rev Endocrinol; 2011 Apr; 7(8):473-84. PubMed ID: 21502982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of RNAi in metabolic diseases.
    Rondinone CM
    Biotechniques; 2006 Apr; Suppl():31-6. PubMed ID: 16629385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.
    Soutschek J; Akinc A; Bramlage B; Charisse K; Constien R; Donoghue M; Elbashir S; Geick A; Hadwiger P; Harborth J; John M; Kesavan V; Lavine G; Pandey RK; Racie T; Rajeev KG; Röhl I; Toudjarska I; Wang G; Wuschko S; Bumcrot D; Koteliansky V; Limmer S; Manoharan M; Vornlocher HP
    Nature; 2004 Nov; 432(7014):173-8. PubMed ID: 15538359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small RNA: can RNA interference be exploited for therapy?
    Wall NR; Shi Y
    Lancet; 2003 Oct; 362(9393):1401-3. PubMed ID: 14585643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concepts in in vivo siRNA delivery for cancer therapy.
    Gondi CS; Rao JS
    J Cell Physiol; 2009 Aug; 220(2):285-91. PubMed ID: 19391103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene silencing mediated by small interfering RNAs in mammalian cells.
    Scherr M; Morgan MA; Eder M
    Curr Med Chem; 2003 Feb; 10(3):245-56. PubMed ID: 12570711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses.
    DeVincenzo JP
    Antivir Ther; 2012; 17(1 Pt B):213-25. PubMed ID: 22311654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs.
    Dykxhoorn DM; Lieberman J
    Annu Rev Biomed Eng; 2006; 8():377-402. PubMed ID: 16834561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [SiRNA technology, the gene therapy of the future?].
    Rácz Z; Hamar P
    Orv Hetil; 2008 Jan; 149(4):153-9. PubMed ID: 18201957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid nanoparticles for short interfering RNA delivery.
    Leung AK; Tam YY; Cullis PR
    Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future promise of siRNA and other nucleic acid based therapeutics for the treatment of chronic HCV.
    Wilson JA; Richardson CD
    Infect Disord Drug Targets; 2006 Mar; 6(1):43-56. PubMed ID: 16787303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
    De Paula D; Bentley MV; Mahato RI
    RNA; 2007 Apr; 13(4):431-56. PubMed ID: 17329355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A perspective on RNA interference-based therapeutics for metabolic liver diseases.
    Alkhouri N; Gawrieh S
    Expert Opin Investig Drugs; 2021 Mar; 30(3):237-244. PubMed ID: 33470860
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent patents in antiviral siRNAs.
    Saravolac EG; Wong JP; Cairns MJ
    Recent Pat Antiinfect Drug Discov; 2010 Jan; 5(1):44-57. PubMed ID: 19807677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vivo siRNA delivery to tumor cells and its application to cancer gene therapy].
    Takahashi Y; Nishikawa M; Takakura Y
    Yakugaku Zasshi; 2007 Oct; 127(10):1525-31. PubMed ID: 17917414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
    Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
    Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide- and Amine-Modified Glucan Particles for the Delivery of Therapeutic siRNA.
    Cohen JL; Shen Y; Aouadi M; Vangala P; Tencerova M; Amano SU; Nicoloro SM; Yawe JC; Czech MP
    Mol Pharm; 2016 Mar; 13(3):964-978. PubMed ID: 26815386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research progress on the development of the strategies for siRNAs delivery in vivo].
    Tang D; Mao A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Aug; 29(4):775-9. PubMed ID: 23016434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.